FIELD: chemistry.
SUBSTANCE: proposed is a neutralization assay method to evaluate candidate vaccines for their ability to interfere with HCMV (human cytomegalovirus). Method includes the following steps: (i) mixing heat inactivated serum from a subject that has been immunized with an HCMV candidate vaccine with an HCMV comprising a fluorescent moiety to form a mixture; (ii) adding 2.5% rabbit complement to the mixture from step (i); (iii) contacting a host cell that is susceptible to infection by HCMV, wherein said host cell is a retinal pigmented epithelial cell of ARPE-19, under conditions that allow infection with the mixture of heat inactivated serum in the presence of rabbit complement from step (ii); (iv) assessing a fluorescence level of the host cell that has been contacted with the mixture by flow cytometry; and (v) determining a level of infection of the host cell based on the assessed fluorescence level.
EFFECT: invention allows to evaluate potential candidate vaccines for neutralizing antibody induction.
20 cl, 5 dwg, 8 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS AND METHODS FOR TREATING CYTOMEGALOVIRUS | 2012 |
|
RU2737530C1 |
CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV | 2012 |
|
RU2611198C2 |
CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV | 2012 |
|
RU2670012C1 |
ANTIGEN DELIVERY PLATFORMS | 2011 |
|
RU2597974C2 |
ANTIBODIES NEUTRALISING HUMAN CYTOMEGALOVIRUS AND USE THEREOF | 2008 |
|
RU2469045C2 |
COMPOSITION CONTAINING HCMV PARTICLES | 2008 |
|
RU2505314C2 |
MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC EPITOPES OF CIRCUMSPOROZOITE PROTEIN PLASMODIUM | 2010 |
|
RU2585228C2 |
HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
VIRAL VECTOR MANUFACTURE | 2014 |
|
RU2658487C2 |
GENES CODING MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMA VIRUS, AND USING THEM | 2008 |
|
RU2494106C2 |
Authors
Dates
2018-07-09—Published
2013-03-27—Filed